Author: Antepowicz, Agata; Habib, Omar; Kirsebom, Freja; Johansson, Cecilia; Gill, Deborah R.; Hyde, Stephen C.
Title: Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection Cord-id: wagf4qpk Document date: 2021_8_3
ID: wagf4qpk
Snippet: Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vec
Document: Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
Search related documents:
Co phrase search for related documents- absolute number and lymphocyte absolute number: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date